Search Results

Critical Path Institute and Centogene N.V. are pleased to announce the signing of a Memorandum of Understanding to advance drug development for lysosomal diseases and improve the quality of life for those impacted by these conditions.

Backed by ARCH Venture Partners, F-Prime Capital and Mubadala Capital, the new company will develop a pipeline of brain-penetrant small molecules to address inflammation, metabolic dysfunction and restoring lysosomal function.

JCR Pharmaceuticals’ Research Presentations at WORLD Symposium ™ 2024 Showcase JR-141 (Pabinafusp Alfa) and Other Investigational Treatments for Lysosomal Storage Disorders.

Denali Therapeutics Inc. (Nasdaq: DNLI) today announced program progress and expected milestones for 2024, which Chief Executive Officer, Ryan Watts, Ph.D., will highlight during a corporate presentation at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9th, at 10:30 a.m. Pacific Time.

M6P Therapeutics, a privately held life sciences company developing next-generation enzyme replacement and gene therapies for lysosomal storage disorders, announced the presentation of promising preclinical data at the 19th Annual WORLDSymposium™, a research conference dedicated to lysosomal diseases being held in Orlando, FL, and virtually Feb. 22-26, 2023.

Arkuda Therapeutics today announced that it entered into an option and asset purchase agreement with Janssen Pharmaceuticals, Inc. (Janssen), a Johnson & Johnson company, which grants Janssen an exclusive option to purchase Arkuda’s portfolio of lysosomal function enhancers.

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system